Infant Colic Treatment With Probiotics

NCT ID: NCT03467334

Last Updated: 2019-07-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

156 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-05-31

Study Completion Date

2019-06-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the efficacy of Bifidobacterium breve CECT7263 and the mixture B. breve CECT7263/Lactobacillus fermentum CECT5716 in the treatment of infant colic. Group 1 will receive B. breve CECT7263 (2x10E8 CFU/day) one dose per day, group 2 will receive B. breve CECT7263 (1x10E8 CFU/day) and L. fermentum CECT5716 (1x10E8 CFU/day) in one dose per day, group 3 (control group) will receive simethicone 20 mg 4 times a day.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Infant colic affects between 3-40% depending on the different criteria used for diagnosis. Recent studies carried out in healthy infants have shown that the consumption of B. breve CECT7263 and L. fermentum CECT5716 during the first months of life are related to a lower risk to present episodes of crying characteristic of infantile colic.

The objective of the present study is to compare the effect of B. brevis and B. brevis\\L mixture. fermentum with respect to simethicone.

It is a multicenter, controlled, randomized, blind, parallel-group, 4-weeks nutritional intervention study which will be conducted in 18 public and private hospitals and health centers from Spain.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Infant Colic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Investigators Outcome Assessors
The control group is the usual treatment that is administered differently (oral drops, 4 times a day) to the 2 research treatments (powder, 1 time a day).

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

B. breve

Group that will receive B. breve CECT7263 one dose per day in a capsule to open and suspend the powder in infant milk or water.

Group Type EXPERIMENTAL

B. breve

Intervention Type DIETARY_SUPPLEMENT

Bifidobacterium probiotic strain at 1E+08 cfu/day

B. breve plus L. fermentum

Group that will receive B. breve CECT7263 and L. fermentum CECT5716 in one dose per day in a capsule to open and suspend the powder in infant milk or water.

Group Type EXPERIMENTAL

B. breve plus L. fermentum

Intervention Type DIETARY_SUPPLEMENT

Probiotic combination at 2E+08 cfu/day

Simethicone 20 mg

Control group that will receive simethicone 4 times (10 drops) a day.

Group Type ACTIVE_COMPARATOR

Simethicone 20 MG

Intervention Type DRUG

Standard treatment for infant colic

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

B. breve

Bifidobacterium probiotic strain at 1E+08 cfu/day

Intervention Type DIETARY_SUPPLEMENT

B. breve plus L. fermentum

Probiotic combination at 2E+08 cfu/day

Intervention Type DIETARY_SUPPLEMENT

Simethicone 20 MG

Standard treatment for infant colic

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Infants from 3 to 12 weeks of age
* Born at least at week 34
* Birth weight equal to or greater than 2000 grams
* Fulfill the criteria of Rome III
* Informed consent signed by parents or guardians

Exclusion Criteria

* Failure to thrive
* Antibiotic treatment less than 2 weeks before the study or during the study
* Take probiotics as a treatment, different from the one that could contain the powdered infant formula
* Abandon breastfeeding and switch to infant formula
* Failure to comply with the study protocol
Minimum Eligible Age

3 Weeks

Maximum Eligible Age

12 Weeks

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

European Regional Development Fund

OTHER

Sponsor Role collaborator

Ministerio de Ciencia e Innovación, Spain

OTHER_GOV

Sponsor Role collaborator

Mónica Olivares Martín; PhD

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mónica Olivares Martín; PhD

Head of the R & D Department

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

José Maldonado, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Specialist in Pediatrics of the Medical-Surgical UGC of Infancy of the University Hospital Complex of Granada (Spain)

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Servicio Andaluz de Salud

Granada, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Spain

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

P040

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Probiotics Strains for Infant Colic
NCT05685030 UNKNOWN PHASE2